Non-arteritic anterior ischaemic optic neuropathy (AION) is thought to be due to occlusion of the posterior ciliary circulation. Raised lipid and fibrino gen concentrations are recognised risk factors for vessel occlusion in cardiovascular disease and stroke but, although suspected as risk factors in non-arteritic AION, they have not been studied in this condition.
Anterior ischaemic optic neuropathy (AION) is a significant cause of visual impairment.! It is char acterised by a sudden painless loss of visual acuity or visual field, associated with a swollen disc. The ischaemia is due to occlusion of the posterior ciliary artery circulation? , 3 In only 10-20% of cases is this associated with temporal arteritis.4-6 The majority of cases are termed non-arteritic AION. In a few of these cases specific conditions have been associated, including: systemic vasculitis,7 mic¥raine,8 blood 10ss,9 abnormalities of coagulation,! glaucoma!! and cataract surgery.!2 However, in most cases the aetiology is unknown. The atherosclerotic process is thought to be a major cause,! but the incidence of risk factors for this process, in patients with non arteritic AION, has not been fully studied. We have therefore performed a case-control study to assess such associations, looking in particular at cholesterol, fibrinogen and smoking. These are recognised risk factors for vessel occlusion in cardiovascular disease and stroke. 13, !4
There is a high incidence of this condition becoming bilatera1.6 If positive associations with these risk factors were found then currently available treatments might help decrease the inci dence of this devastating outcome.
PATIENTS AND METHODS
We studied 41 consecutive patients with an age range of 52-83 years (mean 66.7 years), 27 men and 14 women, who were diagnosed as having non-arteritic AION between 1986 and 1992 (Table I ). All were Caucasian. Two patients presented with second eye involvement. Forty-one age-, sex-and race-matched controls were randomly selected from a pre-operative cataract assessment clinic. The same information was obtained from these subjects, with their consent.
The patients were age-matched within 5-year bands.
The mean age of the controls was 66.9 years.
Cataract patients were used as controls as they are routinely examined and investigated prior to surgery and this enabled age and sex matching to be carried out from a group of patients from the same geographical area. The group was also a hospital based population, as was the AI ON group. Cataract patients may not be as healthy as a completely random selection of patients (for example they are more likely to be diabetic I5 ), but this makes any 
RESULTS
Raised fibrinogen, cholesterol and smoking were found to be statistically significantly associated with non-arteritic AION (Tables II, III ?ave been suspected for some time, 1 9 but the picture IS not clear cut. Hypertension has been found to be associated in patients under 65 years.4-6 Diabetes has been found to be associated, in one study, in patients of all ages, 6 but in other studies a relationship was seen only in patients under 64 years.4,5. 2 D Pre-existing cardiovascular disease was found to be associated in one study, but again not in another.5 (These findings are summarised in Table IV .) We did not find an association with hypertension, diabetes or coexistent atherosclerotic disease, but the number of patients studied was relatively small and only 18 of them were under 65 years. We did find a significant association between non arteritic AION and serum cholesterol and fibrinogen levels, as well as smoking. Smoking can affect the level of fibrinogen and especially lower the level of fibrinolytic activity? 1 However, fibrinogen has been found to be an independent risk factor for ischaemic heart disease and stroke, after adjusting for other risk factors, in particular cholesterol and smoking 13 , 1 6,22 , 23 I th ' t d f h 18 . . n IS s u y, 0 t e patients with raised fibrinogen and AION, 9 were smokers and 9 were not, suggesting that raised fibrinogen is also an independent risk factor for non-arteritic AION. Fibrinogen is a significant component in the complex balance of thrombotic and fibrinolytic factors, and elevated levels may encourage the formation of thrombus on atheromatous plaques? 2 Variations in concentrations of other factors may also be impor tant in predisposing to the development of non arteritic AION.to High total cholesterol concentra tions are associated with ischaemic heart disease.14 This is due to high plasma levels of low density lipoprotein (LDL). It is thought that LDL undergoes an oxidative modification enabling its uptake by rnacrophages, leading to the development of fatty streaks, the first stage in the formation of athero sclerotic plaques. LDL also affects platelet aggrega-. 2 4 S k' bon. mo mg has been found to be an important risk factor in the development of non-arteritic AION 27 In the Northwick Park Study the mean interval between finding a raised fibrinogen concentration and an ischaemic heart disease event was 9 years?8
Lowering blood cholesterol concentrations has been found to decrease the incidence of ischaemic h d· 2 9 eart Isease.
At present there is no specific method of lowering fibrinogen, but low-dose aspirin may have a beneficial effect. In view of the other coagulation abnormalities that may be found, warfarin has even been suggested as a possible preventive therapy against recurrence of AION, in selected cases.]() The finding of a raised level of fibrinogen does, however, identify patients at risk of cardiovascular disease and so encourages the need to modify other risk factors, such as hypertension, smoking and lifestyle. A previous study has suggested that cessation of smoking reduces the risk of developing non-arteritic AION to that of the non-smoking population?5
These data raise the possibility that an aggressive therapeutic regimen to lower multiple risk factors could be successful in reducing the rates of recurrence of AI ON, as has been demonstrated with a similar approach in patients with retinal vein occlusion.3D Indeed preliminary results from follow up of our patients who have been treated with this approach show that only 13% (5/39) of the patients have developed bilateral AI ON over an average follow-up of 27 months. This is encouraging, as an overview of previous studies found the incidence of bilateral involvement to vary from 10.5% to 73% .6 However, follow-up did continue for up to 10 years in some studies.6 K , ey , words: Anterior ischaemic optic neuropathy, Cholesterol. Flbnnogen, Smoking,
